BioCentury
ARTICLE | Clinical News

CVX-060: Phase Ib/II data

June 4, 2012 7:00 AM UTC

Pfizer reported data from 34 patients with solid tumors in the Phase Ib portion of an open-label, U.S. Phase Ib/II trial showing that IV CVX-060 given at its recommended Phase II dose of once-weekly 1...